Louis, Edouard

Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease

The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature

Inflammatory Bowel DiseaseGenetic Associations and Epidemiology

Cited by 4,722

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

the NIDDK IBD Genetics Consortium, Barrett, J. C., the Belgian-French IBD Consortium, the Wellcome Trust Case Control Consortium, Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rioux, J. D., Brant, S. R., et al. (2008) · Nature Genetics

Inflammatory Bowel DiseaseGenetic Associations and Epidemiology

Cited by 2,593

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci

Franke, A., McGovern, D. P. B., Barrett, J. C., Wang, K., Radford-Smith, G. L., Ahmad, T., Lees, C. W., Balschun, T., Lee, J., Roberts, R., et al. (2010) · Nature Genetics

Inflammatory Bowel DiseaseGenetic Associations and Epidemiology

Cited by 2,520

Fine-mapping inflammatory bowel disease loci to single-variant resolution

International Inflammatory Bowel Disease Genetics Consortium, Huang, H., Fang, M., Jostins, L., Umićević Mirkov, M., Boucher, G., Anderson, C. A., Andersen, V., Cleynen, I., Cortes, A., et al. (2017) · Nature

Genetic Associations and EpidemiologyInflammatory Bowel Disease

Cited by 611

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Feagan, B. G., Sandborn, W. J., D'Haens, G., Panés, J., Kaser, A., Ferrante, M., Louis, E., Franchimont, D., Dewit, O., Seidler, U., et al. (2017) · The Lancet

Inflammatory Bowel DiseasePsoriasis: Treatment and Pathogenesis

Cited by 451

Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease

Momozawa, Y., Mni, M., Nakamura, K., Coppieters, W., Almer, S., Amininejad, L., Cleynen, I., Colombel, J.-F., de Rijk, P., Dewit, O., et al. (2011) · Nature Genetics

Inflammatory Bowel DiseaseGenetic Associations and Epidemiology

Cited by 189

Effect of 5-Hydroxytryptophan on Fatigue in Quiescent Inflammatory Bowel Disease: A Randomized Controlled Trial

Truyens, M., Lobatón, T., Ferrante, M., Bossuyt, P., Vermeire, S., Pouillon, L., Dewint, P., Cremer, A., Peeters, H., Lambrecht, G., et al. (2022) · Gastroenterology

Inflammatory Bowel DiseaseTryptophan and brain disorders

Cited by 48

Challenges and opportunities in IBD clinical trial design

Dubinsky, M. C., Collins, R., Abreu, M. T., Abreu, M. T., Collins, R., Dubinsky, M. C., Jairath, V., Lewis, J. D., Lindsay, J., Merad, M., et al. (2021) · Gastroenterology

Inflammatory Bowel DiseaseStatistical Methods in Clinical Trials

Cited by 34